[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,213,829
  • Shares Outstanding, K 57,893
  • Annual Sales, $ 868,450 K
  • Annual Income, $ 158,690 K
  • EBIT $ 190 M
  • EBITDA $ 214 M
  • 60-Month Beta 0.96
  • Price/Sales 2.59
  • Price/Cash Flow 12.20
  • Price/Book 2.25

Options Overview Details

View History
  • Implied Volatility 62.92% (-6.89%)
  • Historical Volatility 50.83%
  • IV Percentile 47%
  • IV Rank 30.69%
  • IV High 127.87% on 09/15/25
  • IV Low 34.16% on 12/17/25
  • Expected Move (DTE 15) 3.67 (9.48%)
  • Put/Call Vol Ratio 6.33
  • Today's Volume 44
  • Volume Avg (30-Day) 801
  • Put/Call OI Ratio 2.57
  • Today's Open Interest 18,281
  • Open Int (30-Day) 8,389
  • Expected Range 35.08 to 42.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.99
  • Number of Estimates 4
  • High Estimate $1.21
  • Low Estimate $0.85
  • Prior Year $0.87
  • Growth Rate Est. (year over year) +13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.25 +20.16%
on 07/16/26
39.96 -3.03%
on 08/04/26
+1.74 (+4.70%)
since 07/06/26
3-Month
28.86 +34.27%
on 05/07/26
39.96 -3.03%
on 08/04/26
+5.97 (+18.21%)
since 05/06/26
52-Week
25.52 +51.84%
on 10/20/25
40.87 -5.19%
on 12/15/25
+4.08 (+11.77%)
since 08/06/25

Most Recent Stories

More News
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper...

HRMY : 38.75 (+1.33%)
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04...

HRMY : 38.75 (+1.33%)
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August...

HRMY : 38.75 (+1.33%)
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

WAKIX® Net Revenue Grew 30% Year over Year to a Record of Approximately $261 Million for Q2 2026 Reaffirms 2026 Net Revenue Guidance of $1.0 Billion to $1.04 Billion...

HRMY : 38.75 (+1.33%)
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual...

HRMY : 38.75 (+1.33%)
Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global...

HRMY : 38.75 (+1.33%)
Harmony Biosciences Q1 Earnings Call Highlights

Harmony Biosciences (NASDAQ:HRMY) reported first-quarter 2026 net product revenue of $215.4 million, a 17% increase from $184.7 million in the prior-year quarter, as the company highlighted continued demand...

HRMY : 38.75 (+1.33%)
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP...

HRMY : 38.75 (+1.33%)
Will Harmony Biosciences Finally Address What Happens After Wakix Patent Expiration?

Barchart Research What to Expect from HRMY Earnings HRMY Generated May 6, 2026 Current Price $32.78 EPS Estimate $$0.76 Consensus Rating Moderate Buy Average Move 6.80% Will Harmony Biosciences Finally...

HRMY : 38.75 (+1.33%)
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony...

HRMY : 38.75 (+1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 40.18
2nd Resistance Point 39.49
1st Resistance Point 39.12
Last Price 38.75
1st Support Level 38.06
2nd Support Level 37.37
3rd Support Level 37.00

See More

52-Week High 40.87
Last Price 38.75
Fibonacci 61.8% 35.01
Fibonacci 50% 33.19
Fibonacci 38.2% 31.38
52-Week Low 25.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.